Semaglutide Maintenance Dose After Reaching Goal Weight

Reaching a goal weight raises a common question in the research literature: what happens to the dose after the climb is over. In semaglutide trials the maintenance dose is usually the same dose a person titrated up to, not a lower one. This article covers the standard maintenance number, what published data show about stopping, and why the right dose is an individual decision made with a licensed clinician. It is reference information only, not medical advice.

Throughout, use the semaglutide calculator to convert any milligram figure into syringe units for your specific vial concentration. The numbers below are general references, not a protocol.

The standard maintenance dose: 2.4 mg

In the STEP weight-management trials, participants titrated over about 16 weeks to a target of 2.4 mg once weekly, and that 2.4 mg dose was carried through the rest of the study as the maintenance dose. So in the research framing, maintenance is not a step-down. The dose that produced the result is generally the dose that continues.

The standard escalation schedule used in trials looks like this:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1.0 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance target)

For the diabetes-focused product, the labeled maintenance range tops out lower (1.0 mg, with 2.0 mg studied), so the 2.4 mg figure is specific to the weight-management formulation. Always match references to the exact product in question.

The 1.7 mg fallback

Not everyone tolerates 2.4 mg. Trial protocols allowed staying at 1.7 mg as a maintenance dose when the higher step was not well tolerated. That makes 1.7 mg the documented fallback rather than an off-script choice. The general principle in the literature is the lowest dose that holds the result, which for many people is 1.7 mg and for others is 2.4 mg.

What the regain data show on stopping

The most cited evidence here is the STEP 1 extension. After participants stopped semaglutide and lifestyle support at week 68, they regained about two-thirds of the lost weight by week 120, roughly one year off the compound. Cardiometabolic markers that had improved also drifted back toward baseline. The STEP 4 withdrawal study showed a similar pattern: people who switched to placebo at week 20 regained weight, while those who continued the dose kept losing.

The research read on this is that GLP-1 agonists act while present, not as a one-time correction. This is why trials studied continued maintenance dosing rather than a fixed stop date. Whether and how to taper or stop is a clinical question, not a self-directed one.

Why the maintenance dose is individualized

Two people at the same goal weight can sit at different maintenance doses. Factors a clinician weighs include side-effect tolerance, how stable the weight is, the formulation and concentration on hand, and the overall health picture. Some protocols in the literature explore lower-frequency or reduced maintenance dosing once a target is held, but the evidence base for that is thinner than for staying at the titrated dose.

If you want to see how a maintenance dose translates to the syringe, the math is concentration-driven. Reconstitute the vial, find your mg-per-mL, then convert to units.

Worked example

Say a 5 mg vial is reconstituted with 1 mL of bacteriostatic water. That gives 5 mg/mL, or 5,000 mcg/mL. On a U-100 insulin syringe, 1 mL equals 100 units, so each unit holds 0.05 mg (50 mcg).

• 2.4 mg maintenance = 2.4 / 0.05 = 48 units
• 1.7 mg fallback = 1.7 / 0.05 = 34 units

Change the water volume and these unit numbers change. Run your own vial through the semaglutide calculator or the general reconstitution calculator so the units match your concentration, not this example. For the conversion logic itself, see semaglutide units per dose.

Key takeaways

• In weight-management trials, 2.4 mg weekly is the standard maintenance dose, carried over from titration.
• 1.7 mg weekly is the documented fallback when 2.4 mg is not well tolerated.
• Stopping is associated with substantial regain (about two-thirds within roughly a year in STEP 1).
• Maintenance dosing is individual; dose and duration decisions belong with a licensed clinician.

For the full titration picture before maintenance, see the semaglutide dosage chart. This content is educational and describes research compounds; it is not medical advice. See our disclaimer.